Related Experiment Video
Updated: Oct 29, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
Inge K Holden1,2, Claus Bistrup2,3, Anna Christine Nilsson2,4
1Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Background:
It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients.
Results:
A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine.
Conclusion:
This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.
More Related Videos
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cell-mediated Immune Responses
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Kidney Transplant I: Introduction

